

Huri Ozdogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9399263/publications.pdf>

Version: 2024-02-01

38
papers

2,074
citations

430874

18
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

2075
citing authors

#	ARTICLE	IF	CITATIONS
1	Late-onset familial mediterranean fever: single-center experience and literature review. Internal and Emergency Medicine, 2022, 17, 1301-1306.	2.0	4
2	Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors. Rheumatology, 2022, 61, SI194-SI196.	1.9	4
3	Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. Journal of Medical Virology, 2022, 94, 3431-3437.	5.0	4
4	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. Rheumatology, 2022, 62, 9-18.	1.9	2
5	Soluble TREM-1 Levels in Familial Mediterranean Fever Related AA-Amyloidosis. Immunological Investigations, 2021, 50, 273-281.	2.0	6
6	Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. Rheumatology, 2021, 60, 2327-2332.	1.9	11
7	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. Rheumatology International, 2021, , 1.	3.0	3
8	Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology, 2020, 59, 3892-3899.	1.9	18
9	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.9	39
10	The efficacy of anti-IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102332.	2.0	11
11	Familial Mediterranean Fever. Presse Medicale, 2019, 48, e61-e76.	1.9	104
12	Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatology International, 2019, 39, 911-919.	3.0	37
13	Polyarteritis nodosa: lessons from 25 years of experience. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 52-56.	0.8	9
14	Familial Mediterranean fever: misdiagnosis and diagnostic delay in Turkey. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 119-124.	0.8	2
15	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International, 2018, 38, 607-622.	3.0	12
16	<i>LACC1</i> Gene Defects in Familial Form of Juvenile Arthritis. Journal of Rheumatology, 2018, 45, 726-728.	2.0	17
17	Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatology International, 2018, 38, 129-136.	3.0	63
18	Canakinumab for the treatment of familial Mediterranean fever. Expert Review of Clinical Immunology, 2017, 13, 393-404.	3.0	37

#	ARTICLE	IF	CITATIONS
19	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology</i> , 2017, 56, 2102-2108.	1.9	84
20	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017, 12, 1059-1067.	2.0	7
21	Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 105.	2.7	41
22	Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 75-81.	0.8	2
23	Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 95-99.	0.8	6
24	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 644-651.	0.9	393
25	Effects of serial casting in the treatment of flexion contractures of proximal interphalangeal joints in patients with rheumatoid arthritis and juvenile idiopathic arthritis: A retrospective study. <i>Journal of Hand Therapy</i> , 2016, 29, 41-50.	1.5	5
26	Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1051-1056.	0.9	83
27	Effect of colchicine on serum lipid levels. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S136.	0.8	1
28	Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. <i>Arthritis Research and Therapy</i> , 2015, 17, 243.	3.5	83
29	The Emerging Treatments in Familial Mediterranean Fever. <i>Rare Diseases of the Immune System</i> , 2015, , 137-157.	0.1	3
30	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 799-805.	0.9	215
31	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 635-641.	0.9	145
32	FMF50: a score for assessing outcome in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 897-901.	0.9	57
33	Development of normative data for cylindrical grasp pressure. <i>International Journal of Industrial Ergonomics</i> , 2011, 41, 509-519.	2.6	5
34	Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement. <i>Pediatrics</i> , 2007, 119, e474-e483.	2.1	230
35	Country as the primary risk factor for renal amyloidosis in familial mediterranean fever. <i>Arthritis and Rheumatism</i> , 2007, 56, 1706-1712.	6.7	243
36	Necrotizing vasculitis associated with familial Mediterranean fever. <i>American Journal of Medicine</i> , 2004, 117, 516-519.	1.5	19

#	ARTICLE	IF	CITATIONS
37	A survey of phenotype II in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 910-913.	0.9	23
38	A familial syndrome of pericarditis, arthritis, camptodactyly, and coxa vara. <i>Arthritis and Rheumatism</i> , 1986, 29, 436-438.	6.7	32